Nephrology Journal Club

Do you struggle to treat patients with FSGS? Are you a fan of sparsentan but asking...what's next? TRPC6 inhibitors have completed a phase 2 study! Are we closing in on a common pathway of FSGS pathology? #NephTwitter #MedTwitter nephjc.com/news/trcpc6inh…

🚨Another #NephJC short 🩳 FINE ONE: Finerenone in Type 1 Diabetes Fine, but does it cross the finish line? Blog by @DrAkshayaJ #NephTwitter #MedTwitter nephjc.com/news/2026/5/4/…

10/10 Final thoughts New 💊, more data= good. Keep an eye out for data manipulation & be a little skeptical. ➡️Up next May 19, 2026: Multifaceted Strategies for Hypertension Control in Low-Income Patients (Mills et al, NEJM, 2026) Join us nephjc.com How we doing?

9/10 I want more info: Blog by @SayaliBThakare @DrSaiVani1 nephjc.com/news/trcpc6inh… VA by @divyaa24 nephjc.com/news/2026/5/3/…

1/10 #NephJC #TenPostNephJC. #NephTwitter In 2026 💊 FDA approved sparsentan for FSGS, an endothelin A/angiotensin II receptor inhibitor. Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰 Article 👇 pubmed.ncbi.nlm.nih.gov/41616795/

👂So, did you hear the one about avacopan and data manipulation?🧮🧮🧮 @hswapnil has added onto our ADVOCATE summary with a "postscript" summary of the controversy. #NephTwitter #MedTwitter nephjc.com/news/advocate?…

Gracias @dra_miliflores, el resumen visual en espanol #NephTwitter #MedTwitter nephjc.com/news/2026/trpc…

💊FSGS precision medications started with AMKD (APOL-1) and inaxaplin. 💊This week we're discussing FSGS and what else is in the pipeline of therapeutics...TRPC6 inhibitors. #NephTwitter #Medtwitter Check out the VA by @divyaa24 nephjc.com/news/2026/5/3/…

Rumor has it the internship applications are still open- no shared birthday with #NephJC required ✨Admiring Raquel's level of dedication ⏰Apply before May 1st

⏰This opportunity has a GFR of zero after May 1st (11:59 pm EST)- NephJC's Editorial Internship is closing 😉Last chance to apply #NephJC nephjc.com/news/nephjc-ed…

⏳ Deadline in a few days! Want to level up your science‑communication game? 👇👇Apply to the #NephJC Editorial Internship and help craft the conversations that move nephrology forward nephjc.com/news/nephjc-ed…

Top ten Hydralazine puns: #NephJC 1. Hydra-lazily😴 2. Hydra-no-razzle-dazzle🎇 3. Hydr-ANCA-zine🔥 4. Hydra-lies-in-wait 🐍 5. Hydro-rail-az-wine 💦🚊az🍷 6. Why-dralazine ❓❓

@eric_weinhandl @NephroSeeker @dra_miliflores @divyaa24 11/10 Thanks for being aboard to #NephJC Flight ✈️ Final call for applications is near ⏳ Fasten your seatbelt… and don’t miss your chance to apply 😉 Until next time @NephJC this was your nephron @dra_miliflores ✍️ nephjc.com/news/nephjc-ed… #TenPostNephJC #NephTwitter

@eric_weinhandl @NephroSeeker @dra_miliflores @divyaa24 10/10 👉 So… is it time to trash hydralazine #NephJC? 🗑️ #TenPostNephJC #NephTwitter #NephSky ➡️ Up next (05/06/26): TRPC6 inhibition in FSGS, a phase 2 trial of BI 764198 pubmed.ncbi.nlm.nih.gov/41616795/

Still ordering hydralazine? 🤔 Beyond case reports, this large cohort compares hydralazine vs ACEi/ARB to estimate real-world vasculitis risk, will this 📉 bias & clarify the answer Read more 👇 pubmed.ncbi.nlm.nih.gov/41838000/ #TenPostNephJC #NephJC #MedTwitter #NephTwitter